Home/Filings/4/0001628280-22-028462
4//SEC Filing

Baldry Mark 4

Accession 0001628280-22-028462

CIK 0001501697other

Filed

Nov 3, 8:00 PM ET

Accepted

Nov 4, 4:18 PM ET

Size

5.6 KB

Accession

0001628280-22-028462

Insider Transaction Report

Form 4
Period: 2022-11-03
Baldry Mark
Chief Commercial Officer
Transactions
  • Award

    Stock Option (right to buy)

    2022-11-03$1.89/sh+341,000$644,490341,000 total
    Exercise: $1.89Exp: 2032-11-03Common Stock (341,000 underlying)
Footnotes (1)
  • [F1]25% of the shares subject to the option shall vest on November 3, 2023, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date.

Issuer

X4 Pharmaceuticals, Inc

CIK 0001501697

Entity typeother

Related Parties

1
  • filerCIK 0001644137

Filing Metadata

Form type
4
Filed
Nov 3, 8:00 PM ET
Accepted
Nov 4, 4:18 PM ET
Size
5.6 KB